98%
921
2 minutes
20
Renal oncocytoma (RO) is a benign renal neoplasm characterized by dense accumulation of dysfunctional mitochondria possibly resulting from increased mitochondrial biogenesis and decreased mitophagy; however, the mechanisms controlling these mitochondrial changes are unclear. ROs harbor recurrent inactivating mutations in mitochondrial genes encoding the Electron Transport Chain (ETC) Complex I, and we hypothesize that Complex I loss in ROs directly impairs mitophagy. Our analysis of ROs and normal kidney (NK) tissues shows that a significant portion (8 out of 17) of ROs have mtDNA Complex I loss-of-function mutations with high variant allele frequency (>50%). ROs indeed exhibit reduced Complex I expression and activity. Analysis of the various steps of mitophagy pathway demonstrates that AMPK activation in ROs leads to induction of mitochondrial biogenesis, autophagy, and formation of autophagosomes. However, the subsequent steps involving lysosome biogenesis and function are defective, resulting in an overall inhibition of mitophagy. Inhibiting Complex I in a normal kidney cell line recapitulated the observed lysosomal and mitophagy defects. Our data suggest Complex I loss in RO results in defective mitophagy due to lysosomal loss and dysfunction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12347756 | PMC |
http://dx.doi.org/10.3390/ijms26157654 | DOI Listing |
Can J Urol
August 2025
Department of Urology, Emory University, Atlanta, GA 30322, USA.
Tumor-to-tumor metastasis (TTM) is a rare phenomenon in which a secondary tumor colonizes within a primary tumor of a different histogenesis. It is hypothesized that TTM is encouraged by conditions that promote increased cell growth and division in the primary tumor, such as hypervascularity and expression of oncogenic cytokines. However, the exact causes of TTM likely vary on a case-by-case basis and are dependent on the microenvironment of both the primary and secondary tumors.
View Article and Find Full Text PDFIntractable Rare Dis Res
August 2025
Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.
Renal oncocytomas are benign renal tumours characterized by a central stellate scar that are indistinguishable on CT/MR imaging from malignant chromophobe renal cell carcinomas (ChrRCCs). Renal oncocytomas and ChrRCCs can be separate entities but can also co-exist on a spectrum in hybrid oncocytic/ chromophobe tumours. In the past, invasive biopsy and pathologic diagnosis has been relied on to differentiate these lesion and direct management.
View Article and Find Full Text PDFClin Genitourin Cancer
August 2025
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:
Objectives: To investigate the clinical characteristics, tumor growth rate, oncologic and renal function outcomes in patients with bilateral, multifocal renal oncocytoma managed with active surveillance and/or surgery.
Materials And Methods: Bilateral, multifocal renal oncocytoma patients were evaluated using clinical, cross-sectional imaging and pathologic records. The cohort was divided into 3 groups: those under active surveillance only, those who underwent surgery in combination with active surveillance, and those who underwent multiple interventions.
Exp Mol Pathol
August 2025
University of Porto - Faculty of Medicine, Pathology Department, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.; ULS São João, EPE, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.; i3S - Instituto de Investigação e Inovação em Saúde, University of Porto, R. Alfredo Alle
Peroxidasin (PXDN), is a heme peroxidase with a critical role in the crosslinking of type IV collagen, being essential for basement membrane integrity. Overexpression of PXDN has been associated with poor clinical outcomes in many cancers; however, little is currently known about its role in renal cell carcinoma (RCC). In this study, we characterized the expression of PXDN in tumour tissue and adjacent non-neoplastic tissue from cases of clear cell renal cell carcinoma (ccRCC), chromophobe RCC (chRCC), and renal oncocytoma using immunohistochemistry.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Urology, UCLA, 405 Hilgard Avenue, Los Angeles, CA 90095, USA.
Renal oncocytoma (RO) is a benign renal neoplasm characterized by dense accumulation of dysfunctional mitochondria possibly resulting from increased mitochondrial biogenesis and decreased mitophagy; however, the mechanisms controlling these mitochondrial changes are unclear. ROs harbor recurrent inactivating mutations in mitochondrial genes encoding the Electron Transport Chain (ETC) Complex I, and we hypothesize that Complex I loss in ROs directly impairs mitophagy. Our analysis of ROs and normal kidney (NK) tissues shows that a significant portion (8 out of 17) of ROs have mtDNA Complex I loss-of-function mutations with high variant allele frequency (>50%).
View Article and Find Full Text PDF